Search hospitals > Illinois > Chicago
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Claim this profileChicago, Illinois 60611
Global Leader in Lymphoma
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Cancer
Conducts research for Lung Cancer
374 reported clinical trials
10 medical researchers
Summary
Robert H. Lurie Comprehensive Cancer Center at Northwestern University is a medical facility located in Chicago, Illinois. This center is recognized for care of Lymphoma, Breast Cancer, Leukemia, Cancer, Lung Cancer and other specialties. Robert H. Lurie Comprehensive Cancer Center at Northwestern University is involved with conducting 374 clinical trials across 221 conditions. There are 10 research doctors associated with this hospital, such as Mark Agulnik, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..Area of expertise
1Lymphoma
Global LeaderStage IV
limited-stage
DLBCL
2Breast Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
Mark AgulnikCity of Hope4 years of reported clinical research
Studies Sarcoma
Studies Tumors
23 reported clinical trials
34 drugs studied
Sunandana ChandraNorthwestern University1 year of reported clinical research
Expert in Melanoma
Expert in Skin Cancer
22 reported clinical trials
31 drugs studied
Devalingam Mahalingam, MBBChBAONorthwestern University5 years of reported clinical research
Studies Solid Tumors
Studies Tumors
16 reported clinical trials
51 drugs studied
Jochen H. Lorch, M.D.Northwestern University3 years of reported clinical research
Studies Cancer
Studies Oral Squamous Cell Carcinoma
15 reported clinical trials
25 drugs studied
Clinical Trials running at Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Acute Myeloid Leukemia
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Leukemia
Cancer
Acute Leukemia
Myeloid Leukemia
Liver Disease
Solid Tumors
Ziftomenib Combinations
for Acute Myeloid Leukemia
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Recruiting1 award Phase 1
Triple-Drug Therapy
for Acute Myeloid Leukemia
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene. Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with AML with the changed FLT3 gene. They cannot have chemotherapy due to old age or other conditions. Before these combined 3 medicines are available as a treatment, the researchers need to understand how they are processed by and act upon the body when given together. In this study, they do this to find a suitable dose for venetoclax and to check for potential medical problems from the treatment. In this study, people newly diagnosed with AML who have the changed FLT3 gene and cannot have chemotherapy can take part. The main aims of this study are: to find suitable doses of gilteritinib, venetoclax and azacitidine as a combined treatment; to learn how they are processed by and act upon the body; to learn the remission rate; to check for medical problems during this treatment. In the study, people will visit the study clinic many times. The first visit is to check if they can take part. People will be asked about their medical history, have a medical examination, and have their vital signs checked. Also, they will have an ECG to check their heart rhythm and have some blood and urine samples taken for laboratory tests. They will have a chest X-ray and a bone marrow sample will be taken. The changed FLT3 gene will be confirmed, either by the bone marrow or a blood sample. This study will be in 2 phases. In Phase 1, different small groups of people will take venetoclax tablets containing lower to higher doses in the combined treatment. The doses of gilteritinib and azacytidine will be unchanged. This is done to find a suitable dose of venetoclax to use in phase 2 of the study. People will take tablets of gilteritinib and venetoclax once a day on a 28-day cycle. They will be given azacytidine as an infusion or an injection just under the skin. This will be for 7 days at the beginning of each 28-day cycle. They will continue cycles of treatment throughout this phase of the study. In Phase 2, more people newly diagnosed with AML with the changed FLT3 gene will take part. They will be treated with the suitable doses of the combined treatment worked out from Phase 1. Treatment will be on a 28-day cycle. People will continue on cycles of treatment throughout this phase of the study. Researchers will work out the remission rate from this phase of the study. In each phase of the study, people can continue with up to 12 cycles of treatment if they can manage any medical problems. People will visit the study clinic many times during their first treatment cycle, and less often during the next cycles. During these visits, medical problems will be recorded and some blood samples will be taken for laboratory tests. On some visits, people will also have their vital signs checked. Bone marrow samples will be taken during cycle 1, and at the beginning of cycle 3. More samples will be taken during the study from people who are not in remission. When people have finished treatment, those who have responded well to treatment and are in remission will be invited to continue with up to 24 more cycles of gilteritinib plus azacitidine. All people taking part in the study will visit the study clinic for an end-of-treatment visit. During this visit, medical problems will be recorded and some blood samples will be taken for laboratory tests. People will have a medical examination, an ECG, and will have their vital signs checked. Also, a bone marrow sample will be taken. There will be a follow-up visit 30 days later to check for medical problems. Then people will visit the clinic or get a phone call every 3 months for up to 3 years. This is to give an update on their current treatment for AML. Some people can have a stem cell transplant during the study if they meet certain study rules. They will pause their study treatment during the stem cell transplant process and continue study treatment afterwards.
Recruiting1 award Phase 1 & 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Robert H. Lurie Comprehensive Cancer Center at Northwestern University?
Robert H. Lurie Comprehensive Cancer Center at Northwestern University is a medical facility located in Chicago, Illinois. This center is recognized for care of Lymphoma, Breast Cancer, Leukemia, Cancer, Lung Cancer and other specialties. Robert H. Lurie Comprehensive Cancer Center at Northwestern University is involved with conducting 374 clinical trials across 221 conditions. There are 10 research doctors associated with this hospital, such as Mark Agulnik, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..
Where is Robert H. Lurie Comprehensive Cancer Center at Northwestern University located?
The Robert H. Lurie Comprehensive Cancer Center at Northwestern University is situated in downtown Chicago, IL, on the Northwestern Memorial Hospital campus. It features several locations: the Galter Pavilion at 201 East Huron Street, the Lavin Family Pavilion at 259 E. Erie St, and the Maggie Daley Center for Women's Cancer Care at 250 E. Superior Street. Discounted parking for patients and visitors is available at the Northwestern Memorial Hospital garage, 222 East Huron Street, and at 321 East Erie Street.
Who should I call to ask about financial aid or insurance network?
**Robert H. Lurie Comprehensive Cancer Center - Financial Assistance and Insurance Contact Information**
**Financial Counseling:**
- For outpatient billing concerns and financial assistance programs, contact a financial counselor at 312-926-6906.
**Billing and Financial Assistance:**
- General billing inquiries: Contact the Admitting Department at 877.924.8200. Available Monday - Thursday, 8 a.m. - 6 p.m.; Friday, 8 a.m. - 5 p.m.
- For financial assistance details, including applications and policies, visit the hospital's website.
- Cost estimates: Use the online cost estimation tool or call 312.227.1333 for assistance.
What insurance does Robert H. Lurie Comprehensive Cancer Center at Northwestern University accept?
The Robert H. Lurie Comprehensive Cancer Center at Northwestern University accepts a variety of insurance plans, including Commercial Plans, Medicaid Plans, and Exchange Plans. For Exchange Plans, specifically, the center accepts the Aetna CVS Health PPO and Individual & Family Plans Chicago Land IL PPO for 2024. It's important to verify your coverage by reviewing your plan's benefit book or contacting your plan's customer service.
What awards or recognition has Robert H. Lurie Comprehensive Cancer Center at Northwestern University received?
The Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago, Illinois, is an NCI-designated Comprehensive Cancer Center, ranking it in the top 1% of cancer centers nationwide. It boasts significant research funding and recognition, highlighted by nine investigators named to the 2023 list of Highly Cited Researchers by Clarivate Analytics, showcasing their broad influence in their respective fields.